Trogenix announces £70M/$95M Series A financing to drive clinical development of potentially curative therapies for aggressive cancers October 7, 2025
Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of RRMM Announced October 7, 2025
OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates October 7, 2025
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology October 7, 2025
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 October 7, 2025
OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer October 7, 2025
Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic October 7, 2025
Initial clinical data for BDC-4182 Ph 1 dose escalation study now expected in 3Q 2026 October 7, 2025
Updated Ph 1 Results of JNJ-1900 (NBTXR3) + Anti-PD-1 in 1L/2L+ Anti-PD-1 Naïve or Resistant R/M-HNSCC Announced October 7, 2025
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent LG-IR NMIBC October 7, 2025
86% Reduction in Tumor Burden Announced in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen October 7, 2025
FDA clears IND application for CDH17-targeting ADC SIM0609 for the treatment of advanced solid tumors October 7, 2025
Alignment with FDA obtained on study design to advance two Ph 3 trials in gastroesophageal cancers (FAPI-GO) and PDAC (FAPI-PRO), with [18F] FAPI-74 October 7, 2025
